Document:

Exhibit 10.152

                                LICENSE AGREEMENT

                  This License Agreement (hereinafter "Agreement"), effective as
of the  date of the last  signature  below  (the  "Effective  Date"),  is by and
between  Bio-Rad  Laboratories,  Inc.,  having an address at 1000  Alfred  Nobel
Drive,  Hercules,  California,  94547,  Bio-Rad Pasteur,  having an address at 3
Boulevard  Raymond  Poincare,  92430  Marnes-la-Coquette  France  (collectively,
"Licensor")  and  Calypte  Biomedical  Corporation,  having an  address  at 5000
Hopyard Road,  Suite 480,  Pleasanton,  California,  94588  ("Calypte")  (each a
"Party" and collectively, the "Parties")

                  WHEREAS,  Licensor has the right to grant a license  under the
Licensed Patents, as defined below;

                  WHEREAS,  Licensor  is willing to grant to Calypte and Calypte
desires  to obtain  from  Licensor a limited,  non-exclusive  license  under the
Licensed Patents;

                  NOW, THEREFORE, the Parties agree as follows:

1.       DEFINITIONS.

                  For the  purpose  of  this  Agreement,  the  terms  set  forth
hereinafter shall be defined as follows:

1.1      Affiliate

                  "Affiliate"  shall  mean,  with  respect  to  an  entity,  any
corporation or other business entity controlled by,  controlling or under common
control with such entity.  For purposes of this Paragraph 1.1,  "control"  shall
mean, with respect to an entity, direct or indirect beneficial ownership of more
than fifty percent (50%) of the voting stock or equity.

1.2      Licensed Patents

                  "Licensed Patents" shall mean those patents listed in Appendix
A and all divisions, continuations, continuations-in-part, and reissues of those
patents and all corresponding foreign counterparts to those patents.

1.3      Licensed Products

                  "Licensed Product(s)" shall mean Urine-based  immunoassays and
serum,  plasma,  oral fluid or whole  Blood-based  Immunoassays (i) which have a
composition  containing an HIV-2 antigen,  (ii) which are manufactured,  used or
sold by Calypte or its Affiliate and are capable of detecting HIV 1/2 antibodies
and/or  antigen only on Calypte's  Point of Care Rapid Test platform (as defined
in  Paragraph  1.5) and (iii)  which,  in the absence of this  Agreement,  would
infringe one or more Valid Patent Claims.

<PAGE>

                  1.4 "Unit of  Licensed  Product(s)"  shall mean that part of a
Licensed Product that is required to test a single sample.

1.5      Calypte's Point of Care Rapid Test Platform

                  Calypte's  Point of Care  Rapid  Test  Platform  shall  mean a
 lateral  flow  immuno-assay  developed,  manufactured  by or for  Calypte or an
 Affiliate of Calypte for the rapid,  point-of-care  detection of  antibodies or
 antigen to HIV-2 including any improvements or  modifications  that may be made
 to such lateral flow, rapid test.

1.6      Point of Care

                  "Point   of   Care"   shall   mean   both   professional   and
over-the-counter point of care.

1.7      Territory

                  "Territory" shall mean worldwide.

1.8      Third Party

                  "Third  Party"  shall mean any party other than  Licensor  and
Calypte or their respective Affiliates.

1.9      Net Sales

                  "Net Sales" shall mean the gross amount invoiced by Calypte or
its  Affiliate  from  the sale of a  Licensed  Product  to a Third  Party in any
country within the Territory, less the following actually incurred by Calypte as
a result of such amounts invoiced:  (1) shipping costs,  insurance costs, custom
duties,  sales tax,VAT and rebates and returns (not to exceed 4% of total annual
Unit volume of Licensed  Products sold by Calypte).  Samples of Licensed Product
provided to end users free of charge shall also be excluded in  determining  Net
Sales  (total of such  items not to exceed  2% of total  annual  Unit  volume of
Licensed Products sold by Calypte).

                  If a  Licensed  Product  is sold in the form of a  combination
product  containing one or more assays that are not Licensed Products under this
Agreement,  Net  Sales  for such  combination  product  shall be  calculated  by
multiplying  actual  Net  Sales  of such  combination  product  by the  fraction
A/(A+B),  where A is the list  price in the  relevant  country  of the  Licensed
Product if sold separately and B is the total list price in the relevant country
of  any  other  assays  in  the  combination  if  sold  separately.   If,  on  a
country-by-country  basis,  the Licensed Product and other assays contained in a
combination  product are not sold  separately in such country,  the Net Sales of
such  combination  product shall be determined by  multiplying  the Net Sales of
such  combination  product  by the  fraction  A/(A+B),  where A is the number of
Licensed Products in the combination product and B is the number of other assays
in the  combination  product  that are not Licensed  Products.  The total of A+B
shall not exceed two (2).

                                      -2-
<PAGE>

1.10     Valid Patent Claim

                  "Valid  Patent  Claim"  shall  mean a  claim  of an  unexpired
Licensed  Patent  that  has not been  revoked,  or held to be  unenforceable  or
invalid by a decision of a court or other  government  agency,  unappealable  or
unappealed within the time allowed for appeal.

2.       GRANTS

         Licensor  grants to  Calypte a  royalty-bearing  non-exclusive  license
(without the right to grant  sublicenses),  under the Licensed Patents, to make,
have made by its Affiliates only, use, import,  export,  offer to sell, and sell
and have sold the Licensed Products in the Territory under Calypte's brand name.
In addition, Licensor grants to Calypte a royalty-bearing  non-exclusive license
(without the right to grant  sublicenses),  under the Licensed Patents,  to have
the Licensed  Products made by Pacific  Biotech Co.,  LTD, 42 Moo 4 Napa,  Moung
Phetchaboon,  Thailand,  which shall be deemed an  Affiliate  for the purpose of
this Agreement.  Except as explicitly provided herein, Calypte does not have the
right to have the Licensed  Products  made by a Third  Party,  without the prior
written consent of Bio-Rad.

3.       FEES AND ROYALTIES, RECORDS AND REPORTS

         3.1 Within  thirty (30) days of the Effective  Date of this  Agreement,
Calypte shall pay to Licensor a license fee of $300,000.  This license fee shall
be non-refundable and not creditable toward royalties.

         3.2 Within six (6) months from the  Effective  Date of this  Agreement,
Calypte shall pay an additional  fee of $700,000 to Licensor.  This fee shall be
non-refundable and not creditable toward royalties.

         3.3

                           (a) Calypte  shall pay to Licensor  royalties  on Net
                  Sales of  Urine-based  Licensed  Products  sold in the  United
                  States,  Japan and Canada,  the greater of 15% of Net Sales of
                  Licensed Products or $0.30 per Unit of Licensed Product.

                           (b) Calypte  shall pay to Licensor  royalties  on Net
                  Sales of Urine-based  Licensed Products sold in any country in
                  the rest of the  world,  the  greater  of 10% of Net  Sales of
                  Licensed Products or $0.15 per Unit of Licensed Product.

         3.4

                           (a) Calypte  shall pay to Licensor  royalties  on Net
                  Sales  of  serum,  plasma  oral  fluid  or  whole  blood-based
                  Licensed Products sold in the United States,  Japan and Europe
                  (as defined in Appendix B), the greater of 15% of Net Sales or
                  $0.50 per Unit of Licensed Product.

                           (b) Calypte  shall pay to Licensor  royalties  on Net
                  Sales  of  serum,  plasma  oral  fluid  or  whole  blood-based
                  Licensed  Products  sold  in any  country  in the  rest of the
                  world,  the  greater  of 12% of Net Sales or $0.25 per Unit of
                  Licensed Product.

                                      -3-
<PAGE>

         3.5

         Notwithstanding  any  contrary  provision  that may be contained in the
present  License  Agreement,  Calypte  agrees to pay the  royalties set forth in
Paragraph  3.3 and 3.4 on all Net Sales of  Licensed  Products  sold  before and
after  the  Effective  Date  of this  Agreement  in  every  country  within  the
Territory, regardless of the country of manufacture of Licensed Products.

         3.6 All  Royalty  payments  under  this  Agreement  shall  be paid on a
quarterly basis,  within sixty (60) days after March 31st, June 30th,  September
30th and December  31st of each year.  The first  royalty  payment shall include
payment of royalties due (if any) on Net Sales of Licensed Products prior to the
Effective  Date.  All payments shall be made in U.S.  dollars.  If Net Sales are
invoiced  in a  currency  other  than  U.S.  dollars,  then  such Net  Sales and
Calypte's royalty obligations based on such Net Sales shall be expressed in U.S.
dollars  converted on the basis of the average  daily New York foreign  exchange
rate for the thirty (30) day period ending on the payment date, as quoted in The
Wall Street Journal.

         3.7 Calypte  shall keep,  and shall require its  Affiliates  (including
Pacific  Biotech Co.) to keep,  full,  true,  and  accurate  books of account in
accordance  with  generally  accepted  accounting  principles  as applied in the
United States,  containing all particulars necessary to show the amounts due and
payable to Licensor under this  Agreement.  Such books and the  supporting  data
shall be open during normal  business hours upon reasonable  advance notice,  at
mutually  agreed  upon  times,  for  three (3)  years  following  the end of the
calendar year to which they pertain (and access shall not be denied  thereafter,
if reasonably  available),  to the inspection of an independent certified public
accountant retained by Licensor. If in dispute, such records shall be kept until
the dispute is settled.  Inspection shall be at Licensor's  expense,  unless the
inspector  concludes  that the  amount  payable  that is  stated  in a report is
understated  by five percent (5%) or more, in which case  Licensor's  reasonable
expenses  incurred in connection  with the inspection  shall be paid by Calypte.
The Parties  agree that any certified  public  accountant  inspecting  Calypte's
books  pursuant  to  this  Paragraph  3.7  shall  retain  as  confidential   all
information, including information about Calypte's finances and customers gained
as a result of that inspection,  with the exception that the accountant shall be
free to  communicate  information to Licensor with respect to (i) whether or not
Calypte is in compliance with the terms of this  Agreement,  (ii) the results of
the  audit  including  financial   information  but  not  customer  information,
information  relating to the accuracy of reports and payments made, and (iii) if
in the  accountant's  professional  opinion  Calypte is not complying or has not
complied with the terms of the Agreement,  the underlying  facts and information
relevant to said non-compliance. Such accountant shall be required to execute an
agreement with Calypte agreeing to the  confidentiality  provisions set forth in
this  Paragraph  3.7.  Information  disclosed  to  Licensor  as a  result  of an
inspection  shall be  subject  to the  confidentiality  provisions  set forth in
Paragraph 4.

                                      -4-
<PAGE>

         3.8 Calypte  shall within sixty (60) days after March 31st,  June 30th,
September  30th and  December  Calypte  shall within sixty (60) days after March
31st,  June  30th,  September  30th  and  December  3lst  of  each  year of this
Agreement, deliver to Licensor a true and accurate written accounting report for
each calendar quarter. Each report, which must be acceptable to Licensor,  shall
in  particular  set forth,  per Licensed  Products  and on a  country-by-country
basis,  (i) the Net Sales,  (ii) all  deductions  from Net Sales made by Calypte
pursuant to Paragraph  1.9,  (iii) the royalties  payable by Calypte to Licensor
pursuant to Paragraph 3, (iv) the quantity of Licensed  Products  sold,  (v) the
name of Licensed Products sold, (vi) the Licensed Products catalog codes,  (vii)
the  quantity  of Units of  Licensed  Products  corresponding  to each  Licensed
Products  catalog code and, upon Licensor's  written request (viii) the quantity
of samples of Licensed Products provided to end users by Calypte.

         3.9  Simultaneously  with the delivery of each royalty report,  Calypte
shall pay to Licensor or to Licensor's  designee,  if designated in writing, the
monies then due under this Agreement for the period covered by the report.  Each
report shall be made and sent by the due date to the following addressees or any
other address that Licensor may provide in writing:

                       Bio-Rad Laboratories, Inc.
                       1000 Alfred Nobel Drive
                       Hercules, California 94547
                       Attention: General Counsel

                                and

                       Bio-Rad Pasteur
                       3 Boulevard Raymond Poincare
                       92430 Marnes-la-Coquette, France
                       Attention: Manager, Legal Affairs

         Each  payment  shall be made and sent by the due date to the  following
Bank Account (or to any other bank  account,  designee or address that  Licensor
may advise in writing):

                        Bank One, N.A.
                        Chicago, Illinois
                        ABA 071000013
                        For credit to Bio-Rad Laboratories, Inc.
                        Account # 58-86988

         3.10 If Calypte shall fail to pay any amount owing under this Agreement
by the due date, the amount owed shall bear interest at the Bank of America, San
Francisco,  California,  USA lending rate ("prime  rate") plus three (3) percent
from the due date until paid.

         3.11  Failure  of  Calypte  to pay  any  amount  specified  under  this
Agreement  within  thirty  (30) days after the due date will give  Licensor  the
right to terminate  this  Agreement  thirty (30) days after notice to Calypte of
the failure to pay which failure has not been cured within the latter thirty-day
period.

                                      -5-
<PAGE>

         3.12 Calypte's  obligation to pay royalties  under this Section 3 shall
exist until the expiration of the last to expire of the Licensed Patents.

         3.13 In the event that any taxes,  withholding or otherwise, are levied
by any taxing  authority in connection  with accrual or payment of any royalties
payable to Licensor  under this  Agreement,  Calypte shall have the right to pay
such taxes to the local tax authorities on behalf of Licensor and the payment to
Licensor of the net amount  due,  after  reduction  by the amount of such taxes,
shall fully satisfy Calypte's royalty obligations under this Agreement, provided
that  appropriate  documentation  of such tax  payment,  including  evidence  of
payment  and  receipt or any other  appropriate  documentation,  is  provided to
Licensor.

4.       CONFIDENTIALITY

         4.1 The Parties shall maintain the confidentiality of the terms of this
Agreement  and shall not disclose the terms to any Third Party without the prior
written consent of the other Parties.  In addition,  Licensor shall maintain the
confidentiality  of any  information  disclosed  to  Licensor as a result of any
inspection  conducted under Paragraph 3.6 and shall use such information  solely
in connection  with this  Agreement.  The  confidentiality  obligations  in this
Paragraph 4 shall not apply where disclosure is required under applicable law or
regulation (including applicable securities laws or regulations),  in which case
the affected  Party shall notify the other Parties in writing in advance of such
disclosure and, upon request,  shall cooperate in seeking confidential treatment
of  the  disclosed  information.  The  Parties  agree  that  the  obligation  of
confidentiality shall also not apply if:

                  (a) the  information  is at the  material  time in the  public
domain through no fault of the receiving Party;

                  (b) the information is required by law to be communicated to a
person who is authorized by law to receive it;

                  (c) the  information  is  required  to be  provided to a stock
exchange, regulatory body or government agency;

                  (d) disclosure of the  information  is  necessarily  made to a
court, or to an arbitrator or administrative tribunal or to legal counsel in the
course of proceedings provided that, in the case of any arbitration proceedings,
Licensor or Calypte, as the case may be, first obtains from each and every party
to those proceedings an undertaking,  enforceable by Licensor or Calypte, as the
case may be, that each party will similarly not divulge or communicate,  without
Licensor  or  Calypte,  as the case may be,  written  consent,  any  information
referred to in this clause;

                  (e)  the  information  is  required  to be  disclosed  to  any
government  agency  whether in  connection  with the  granting of any license or
otherwise,  but such disclosure is to be made only with the consent of the Party
not disclosing the information; or

                  (f) the  disclosure  is made to  effect  registration  of this
Agreement with a Patent Office or other Industrial Property Authority.

                                      -6-
<PAGE>

         4.2 All press  releases  relating to this  Agreement  shall require the
prior  approval of  authorized  representatives  of Licensor and Calypte,  which
approval shall not be unreasonably  withheld or delayed. The Parties acknowledge
that it is their intention to agree upon an appropriate  press release regarding
the signing of this Agreement.

5.       COMPLIANCE AND QUALITY

         5.1 In the exercise of any and all rights and in performance hereunder,
it shall be the duty of  Calypte  to  comply  fully  with all  applicable  laws,
regulations  and  ordinances  and to  obtain  and keep in effect  any  licenses,
permits and other governmental approvals (federal,  state or local) necessary or
appropriate to carry on Calypte's activities hereunder.

         5.2  Licensor  does not approve or endorse  Licensed  Products  sold by
Calypte in any way or for any purpose.  Quality and quality control according to
standards and requirements  that may exist in the marketplace from time to time,
are the sole responsibility of Calypte.

6.       ASSIGNMENT

                  This Agreement may not be assigned by Calypte, by operation of
law, merger, change in ownership or control, including acquisition of the assets
or change in  ownership  or control of the stock of  Calypte,  without the prior
written  consent of Licensor.  The term  "change in ownership or control"  shall
have the meaning set forth in Section 8.6.

7.       WARRANTY, NEGATION OF WARRANTIES AND INDEMNITY

         7.1  Licensor  warrants  that it has  the  right  to  enter  into  this
Agreement and grant the license granted to Calypte herein.

         7.2 Nothing in this Agreement  shall be construed as: (a) a warranty or
representation  by Licensor as to the validity or scope of any Licensed  Patent;
(b) a warranty or representation that the practice under the Licensed Patents is
or will be free from infringement of patents of Third Parties;  (c) an authority
or obligation to sublicense or to sue Third Parties for infringement; (d) except
as  expressly  set forth  herein,  conferring  the right to use in  advertising,
publicity or otherwise, in any form, the name of, or any trademark or trade name
of Licensor;  (e) conferring by implication,  estoppel or otherwise any license,
immunity or right under any patent  owned by or licensed to Licensor  other than
the  Licensed  Patents,  regardless  of  whether  such  patent  is  dominant  or
subordinate to the Licensed Patents;  (f) an obligation to furnish any know-how;
or (g) creating any agency,  partnership,  joint venture or similar relationship
between Licensor and Calypte.

         7.3 Licensor makes no express or implied  warranties of merchantability
or  fitness  for a  particular  purpose.  Licensor  shall not be liable  for any
consequential damages or lost profits of Calypte.

         7.4 Calypte shall assume full  responsibility  for its operation  under
the Licensed Patents and shall defend, indemnify and hold Licensor harmless from
and against all liability,  demands,  damages,  expenses  (including  reasonable
attorneys' fee) and losses for death, personal injury, illness,  property damage
or any other  injury or damage,  including  any damages or  expenses  arising in
connection  with  state  or  federal   regulatory   action,   arising  from  the
manufacture, use or sale of Licensed Products.

                                      -7-
<PAGE>

         7.5 BioRad shall indemnify and hold Calypte,  its directors,  officers,
agents or  employees,  or any of its  Affiliates or their  directors,  officers,
agents  or  employees  (each,  a  "CALYPTE  PARTY")  harmless  from  any and all
liability,  damage,  loss,  cost  or  expense  (including,  without  limitation,
reasonable  attorneys'  fees and  expenses)  resulting  from any claims or suits
brought  against a Calypte  Party by a Third Party arising as a direct result of
(i) Bio-Rad's breach of any of the  representations or warranties made by BioRad
in this Agreement,  or (ii) any Third Party claim arising from Bio-Rad's  breach
of any of such representations or warranties.

         7.6 WITHOUT  LIMITING THE  INDEMNITY  OBLIGATIONS  OF EACH PARTY ABOVE,
NEITHER  PARTY  SHALL  BE  LIABLE  TO  THE  OTHER  PARTY  FOR  ANY   INCIDENTAL,
CONSEQUENTIAL, SPECIAL, OR PUNITIVE DAMAGES OF ANY KIND OR NATURE.

8.       TERM AND TERMINATION

         8.1 This  Agreement,  unless sooner  terminated in accordance  with its
terms, shall continue until the expiration of the last-to-expire of the Licensed
Patents.

         8.2 This  Agreement  shall  terminate  upon a holding of  invalidity or
unenforceability of all Licensed Patents by a final court decision from which no
appeal is or can be taken.

         8.3 This  Agreement  may be  terminated  by Calypte  by giving  written
notice to Licensor.  The termination shall be effective six (6) months after the
notice.  If  the  Agreement  is  terminated  by  Calypte,  Calypte  shall  cease
manufacturing  and selling  Licensed  Products as of the  effective  date of the
termination.

         8.4 The unappealable decision of a court or administrative body finding
Licensor  liable or culpable  due to Calypte's  manufacture  or sale of Licensed
Products  covered by this  Agreement  shall give Licensor the right to terminate
this  Agreement  immediately  upon  notice,  unless  Calypte  obtains a complete
release of Licensor and fully indemnifies Licensor for such liability.

         8.5 This Agreement  shall  terminate upon (i) an adjudication of either
Party as bankrupt or insolvent,  or admission in writing of its inability to pay
its  obligations as they mature;  (ii) an assignment of this Agreement by either
Party for the benefit of creditors;  (iii) the  appointment  of, or either Party
applying for or consenting to the appointment of, a receiver, trustee or similar
officer for a substantial  part of its property;  (iv) the institution of or any
act of either Party  instituting  any  bankruptcy,  insolvency  arrangement,  or
similar proceeding;  or (v) the issuance or levy of any judgment,  writ, warrant
of attachment or execution or similar process against a substantial  part of the
property of either Party. The Party causing such termination  under this Section
8.5 may apply for  reinstatement of this Agreement if either of conditions (iii)
or (v) is removed within ninety (90) days.

                                      -8-
<PAGE>

         8.6 Unless prior  consent is given by Licensor,  Licensor may terminate
this Agreement immediately on notice upon any change in the ownership or control
of Calypte or of its  assets.  For such  purposes,  a "change  in  ownership  or
control"  shall  mean that 50% or more of the voting  stock of  Calypte  becomes
subject to the ownership or control of a person or entity,  or any related group
of persons or entities acting in concert, which person(s) or entity(ies) did not
own or  control  such  portion of voting  stock on the  Effective  Date  hereof.
Licensor shall have the same right to terminate upon any transfer of 50% or more
of the assets of Calypte.

         8.7 Upon any  breach  of or  default  of a  material  term  under  this
Agreement  by Calypte  (except for a payment  default  covered  under  Paragraph
3.11),  Licensor may terminate this Agreement upon sixty (60) days after receipt
of written  notice.  Licensor  will  withdraw  such notice if, during the notice
period, Calypte fully cures such breach or default.

         8.8 Upon  expiration  or  termination  of this  Agreement,  all  rights
granted to Calypte shall revert to or be retained by Licensor.

         8.9  Notwithstanding  the above, if Licensor  terminates this Agreement
for any reason other than an uncured payment  default by Calypte,  Calypte shall
have the right to dispose of its existing  inventory of Licensed Products and to
complete all outstanding  orders for Licensed Products for a period of up to six
(6) months  after the  effective  date of  termination;  provided  that  Calypte
fulfills its  obligations to report and pay royalties on such Licensed  Products
in accordance with this Agreement.

         8.10 Effect of Expiration or Termination

                  (a) Upon  termination of this  Agreement,  Licensor shall have
the right to retain any sums  already  paid by Calypte  hereunder,  and  Calypte
shall pay all sums accrued hereunder which are then due.

                  (b)  Paragraphs  3.7, 3.8,  3.9,  3.10, 4, 7.2, 7.4, 7.5, 7.6,
8.8,  8.9,  10.1 and 10.2 shall  survive any  termination  or  expiration of the
Agreement.

9. COUNTERPARTS

                  This  Agreement  may be signed in any number of  counterparts,
all of which taken together and when delivered shall constitute one and the same
instrument.  Any one of the Parties may enter into this Agreement by signing any
such counterpart.

10.      GENERAL

         10.1 This  Agreement  constitutes  the  entire  agreement  between  the
Parties as to the subject matter hereof, and supercedes all prior  negotiations,
representations,  agreements and understandings.  This Agreement may be modified
or amended only by a writing executed by authorized  representatives  of each of
the Parties.

         10.2 Any notice  required or  permitted  to be given by this  Agreement
shall be given by postpaid,  first class,  registered  or certified  mail, or by
courier,  properly  addressed to the other party at the  respective  address set
forth herein or another address that may be provided by written notice of either
Party to the other Party:

                                      -9-
<PAGE>

                  If to Licensor:

                                Bio-Rad Laboratories, Inc.
                                1000 Alfred Nobel Drive
                                Hercules, California 94547
                                Attention: General Counsel

                                         and

                                Bio-Rad Pasteur
                                3 Boulevard Raymond Poincare
                                92430 Mames-la-Coquette France
                                Attention: Manager, Legal Affairs

                  If to Licensee:

                                 Calypte Biomedical Corporation
                                 5000 Hopyard Road, Suite 480
                                 Pleasanton, CA 94588
                                 Attention: Richard D. Brounstein
                                 Executive Vice President

         10.3 Force Majeure

                  If the performance of any part of this Agreement by any Party,
or of any  obligation  under this  Agreement  (with the  exception of payment of
royalties),  is prevented, by reason of acts of God, fire, earthquakes,  acts of
war,  civil unrest or other similar cause beyond the control of the Party liable
to perform, unless conclusive evidence to the contrary is provided, the Party so
affected  shall,  upon giving written notice to the other Party, be excused from
such performance  provided that the affected Party shall use reasonable  efforts
to avoid or remove such causes of non-performance and shall continue performance
with  the  utmost  dispatch   whenever  such  causes  are  removed.   When  such
circumstances arise, the Parties shall discuss what, if any, modification of the
terms of this  Agreement  may be  required  in order to arrive  at an  equitable
solution.

11.      GOVERNING LAW AND VENUE.

         11.1 This Agreement  shall be construed and enforced in accordance with
the laws of the State of California,  USA without giving effect to its conflicts
of law principles.  The Parties agree that the exclusive  jurisdiction and venue
for any dispute or controversy  arising from this Agreement  shall be the courts
in California, USA.

         11.2 If any  provision of this  Agreement is held or  discovered  to be
illegal,  invalid or unenforceable in any jurisdiction,  all other provisions of
this  Agreement  shall be  deemed  valid  and  enforceable  to the  full  extent
possible.

                                      -10-
<PAGE>

                  IN WITNESS  WHEREOF,  Licensor and Calypte have  executed this
Agreement as of the date of the last signature below.

<TABLE>
<CAPTION>
<S>                                           <C>
BlO-RAD PASTEUR                               CALYPTE BIOMEDICAL CORPORATION

By:  /s/ Patrick Bugeon                       By: /s/ Richard D. Brounstein
     ----------------------------------           -------------------------------------

Name:  Patrick Bugeon                         Name: Richard D. Brounstein
      -------------------------------               ---------------------------------

Title:   CEO                                  Title:  Executive Vice President and Chief
                                              Financial Officer
Date:  September 7, 2004
      ------------------
                                              Date: August 23, 2004
                                              For Consent Only:
BlO-RAD LABORATORIES, INC.                    INSTITUT PASTEUR

By: /s/ Sanford S. Wadler                     By: /s/ C. Policard
    -----------------------------------           ------------------------------------

Name: Sanford S. Wadler                       Name:  C. Policard
                                                    ------------

Title: Vice President and General Counsel     Title: EVP Business Development
                                                     --------------------------------

Date: 9/28/04                                 Date: Feb. 17, 2004
      -------------------------------               --------------------------------
</TABLE>

                                      -11-
<PAGE>

                                LICENSE AGREEMENT

                                   APPENDIX A

LICENSED PATENTS

HIV-2 (Foundational)

EP 0239 425
EP 0 320 495
EP 284 383
EP 283 327
US 4,839,288
US 5,030,718
US 5,055,391
US 5,066,782
US 5,268,265
US 5,364,933
US 5,051,496
US 5,770,703
US 5,830,641
US 5,079,342
US 6,048,685
US 6,162,439
US 6,261,762
US 6,265,149
US 6,322,964
US 5,306,614
US 5,580,739
US 6,518,015

                                  Appendix A-1
<PAGE>

                                LICENSE AGREEMENT

                                   APPENDIX B

Countries comprising Europe:

Andorra                         Macedonia
Austria                         Malta
Belarus                         Moldova
Belgium                         Monaco
Bosnia and Herzegovina          Netherlands
Bulgaria                        Norway
Croatia                         Poland
Czech Republic                  Portugal
Denmark                         Romania
Estonia                         Russia
Finland                         San Marino
France                          Slovakia
Germany                         Slovenia
Greece                          Spain
Hungary                         Sweden
Iceland                         Switzerland
Ireland                         Turkey
Italy                           Ukraine
Latvia                          United Kingdom
Liechtenstein
Lithuania                       Vatican City
Luxembourg                      Yugoslavia (Serbia and Montenegro)Exhibit 10.151

               LICENSE AGREEMENT AND TECHNOLOGY TRANSFER AGREEMENT

       THIS  AGREEMENT  is made  as of the  30th  day of  September,  2004  (the
"Effective Date"), by and between CALYPTE BIOMEDICAL CORPORATION ("Calypte"),  a
corporation  organized under the laws of the State of Delaware,  U.S.A.  and ANI
BIOTECH OY ("Ani"),  a  corporation  organized  under the laws of the country of
Finland.

                                    RECITALS

       WHEREAS, Calypte develops, manufactures, markets and sells human in vitro
clinical  diagnostic tests for the detection of human  infectious  agents in the
worldwide professional clinical diagnostic markets.

       WHEREAS, Ani develops,  manufactures,  markets and sells various human in
vitro  clinical  diagnostic  rapid tests under their own brand name or the brand
name of other parties for the worldwide  professional and over-the-counter (OTC)
clinical  diagnostic  markets,  and has applied for patents  describing  certain
lateral-flow rapid test devices and sample applicators.

       WHEREAS,   Ani  desires  to  license  and  transfer  to  Calypte  certain
technology owned by Ani that is related to the development, manufacture and sale
of certain human in vitro clinical diagnostic rapid tests.

       WHEREAS, Calypte desires to develop,  manufacture and sell on a worldwide
basis in the professional and OTC clinical  diagnostic  markets certain human in
vitro clinical diagnostic rapid tests based on technology owned by Ani.

       NOW THEREFORE, the parties hereto agree as follows:

1. Definitions.

         1.1.   "Affiliate"   shall  mean  any  corporation  or  other  business
enterprise  controlled by,  controlling  or under common control by Entity.  For
purposes of this  paragraph,  "control"  shall mean,  with respect to an entity,
direct or indirect beneficial  ownership of more than fifty percent (50%) of the
voting stock or equity.

         1.2.  "Analytes"  shall  mean  HIV,  HPV,  Hepatitis  B,  Hepatitis  C,
Syphilis, Gonorrhea, and Chlamydia.

         1.3.  "Best  Price"  shall mean the actual  number of shares of Calypte
common stock  transferred  to Ani at any given time which shall be determined by
using the 5-day average  closing stock price for Calypte  common stock as listed
on the  American  Stock  Exchange  (AMEX)  immediately  before  the date of said
transfer,  provided  however,  the price at the time of  transfer is equal to or
greater than the Threshold Price.

                                       1
<PAGE>

         1.4  "Confidential  Information"  of a party shall  include any and all
material  and  information  of such party  whether  identified  as  confidential
information or not, including,  without limitation,  ideas,  inventions (whether
patentable  or not),  designs,  product  concepts,  improvements,  manufacturing
processes,  quality standards,  trade secrets, technical information relating to
ongoing research and development, business strategies, marketing plans, customer
lists, and financial data.

         1.5. "Currency Exchange Rate" shall mean the conversion from US Dollars
to Euros at the exchange  rates posted by the Federal  Reserve Bank of New York,
representing  the  12  Noon  Eastern  Time  buying  rates  on the  day  of  said
conversion.

         1.6. "Entity" shall mean any corporation,  partnership,  joint venture,
or other such business organization.

         1.7.  "Field of Use" shall mean human in vitro clinical  diagnostic and
non-therapy screening rapid tests.

         1.8.  "Improvement"  shall mean all improvements and modifications made
to Licensed  Technology or to Manufacturing  Equipment by Ani during the term of
this Agreement.

         1.9.  "License  Fee" shall mean the  license fee set forth in Section 3
hereof payable by Calypte to Ani for the licenses granted hereunder.

         1.10. "Licensed Products" shall mean human in vitro clinical diagnostic
and non-therapy  screening tests  incorporating  Licensed  Technology  which are
designed by Calypte to detect  Analytes in human blood,  serum,  plasma,  urine,
oral fluids, or urogenital swabs.

         1.11.  "Licensed   Technology"  shall  mean  human  in  vitro  clinical
diagnostic and  non-therapy  screening rapid test and sample  applicator  device
technology  described in: (i) European Patent  Application  04003603.0  filed on
February   18,  2004,   and  all  issues,   reissues,   amendments,   divisions,
continuations,  continuations-in-part,  and corresponding  foreign  counterparts
thereof; (ii) Finnish Patent Application FI200040825 filed on June 15, 2004, and
all     issues,     reissues,      amendments     divisions,      continuations,
continuations-in-part,  and corresponding  foreign  counterparts  thereof;  and,
(iii) all confidential  know-how  proprietary to Ani needed to assist Calypte in
developing and manufacturing Licensed Products.

         1.12.  "Manufacturing  Equipment" shall mean all equipment set forth in
Section 5.1 and listed in Exhibit A.

         1.13.  "Net Sales" shall mean the gross  amount  invoiced by Calypte or
its Affiliate  from the sale of a Licensed  Products to a Third Party within the
Territory and Field of Use, less the following actually incurred by Calypte as a
result of such amounts invoiced: shipping costs, insurance costs, custom duties,
sales tax, VAT, promotional discounts, rebates and returns. If Licensed Products
are sold in the form of a combination  product containing one or more diagnostic
tests that are not Licensed  Products under this  Agreement,  Net Sales for such
combination  product shall be calculated by multiplying actual Net Sales of such

                                       2
<PAGE>

combination  product by the fraction  A/(A+B),  where A is the list price in the
relevant  country of the Licensed  Product if sold separately and B is the total
list  price  in the  relevant  country  of any  other  diagnostic  tests  in the
combination if sold separately.  If, on a country-by-country basis, the Licensed
Products and other diagnostic  tests contained in a combination  product are not
sold separately in such country, the Net Sales of such combination product shall
be determined by multiplying  the Net Sales of such  combination  product by the
fraction A/(A+B),  where A is the number of Licensed Products in the combination
product and B is the number of other diagnostic tests in the combination product
that are not Licensed Products. The total of A+B shall not exceed two (2).

         1.14.  "Territory" shall mean the worldwide  professional and OTC human
in vitro clinical diagnostic markets.

         1.15.  "Third  Party" shall mean any party other than Calypte or Ani or
an Affiliate of either Calypte or Ani.

         1.16. "Threshold Price" shall mean a per share price for Calypte common
stock equal to or greater than $0.40.

         1.17.  "Valid  Patent  Claims"  shall  mean any claim of any  unexpired
patent covering  Licensed  Technology  that has not been revoked,  or held to be
unenforceable  or invalid by a decision of a court or other  government  agency,
unappealable or unappealed within the time allowed for appeal.

2. Grants and Licenses.

         2.1.  Subject to payment of the  License Fee set forth in Section 3 and
royalties on net sales set forth in Section 4 as well as  compliance  with other
terms of this  Agreement,  Ani  grants  Calypte  the  following  royalty-bearing
licenses to Licensed  Technology and any Improvement  within the Field of Use in
the Territory:

                  2.1.1.  Ani grants Calypte an exclusive  license to make, use,
develop, have developed, manufacture, have manufactured, offer to sell, sell and
have sold Licensed Products utilizing urine or oral fluid as the sample material
under the Calypte brand name or the brand name of a Third Party; and,

                  2.1.2.  Ani grants  Calypte a  non-exclusive  license to make,
use, develop,  have developed,  manufacture,  have manufactured,  offer to sell,
sell  and have  sold  Licensed  Products  utilizing  blood,  serum,  plasma,  or
urogenital swab as the sample material under the Calypte brand name or the brand
name of a Third Party.

         2.2.  Calypte  shall  have the right to  sublicense  to  Affiliates  of
Calypte the  licenses  granted in this  Section 2.  Calypte  shall secure and be
fully liable that all sublicensees  comply with all the terms of this Agreement,
as applicable.

                                       3
<PAGE>

         2.3.  Calypte  shall be  liable  for all  claims of  product  liability
resulting  from  the  manufacturing,  marketing,  sale and  distribution  of the
Licensed Products by Calypte, its Affiliates and its distributors. Calypte shall
indemnify  and hold  harmless Ani, its  directors,  employees  and  stockholders
against any and all third party  product  liability  claims  resulting  from the
manufacturing, marketing, sale and distribution of the Licensed Products.

3. License Fee.

         3.1. In consideration of the grant of the licenses set forth in Section
2, Calypte shall pay Ani a non-refundable License Fee as follows:

                  3.1.1.  Three Hundred Thousand Euros (300,000 euro) payable in
cash or in shares of Calypte common stock, pursuant to Section 7.1.2 and Section
7.1.2.1,  upon the  Effective  Date,  or within five (5) business days after the
effectiveness of the Registration Statement set forth in Section 7.1.1; and,

                  3.1.2.  Seven Hundred Thousand Euros (700,000 euro) payable in
shares of registered Calypte common stock, or cash, or a combination thereof, at
Calypte's sole discretion in seven (7) equal monthly installments of One Hundred
Thousand  Euros  (100,000  euro) each;  the first  installment  payable five (5)
business days after the effectiveness of the Registration Statement set forth in
Section  7.1.1,  and each  subsequent  installment  payable  on a monthly  basis
thereafter.

         3.2.  The License Fee paid by Calypte in Section 3.1 shall give Calypte
the right to incorporate any Improvement  made by Ani into Licensed  Products at
no additional cost to Calypte.

4. Royalties.

         4.1. Calypte shall pay Ani royalties on Net Sales of Licensed  Products
according to the royalty rate schedule set forth in Exhibit B attached hereto.

                  4.1.1.  In the event Licensed  Products  contain more than one
Analyte per rapid test device, the royalty rate for such Licensed Products shall
be equal to the numerical  average of the individual  royalty rates set forth in
Exhibit B attached hereto for the individual Analytes contained in such Licensed
Products.

         4.2. Calypte's  obligation to pay royalties hereunder shall exist until
the expiration of the last of any Valid Patent  Claims.  In the event no patents
covering  Licensed  Technology  issue in the United  States of America and it is
evident that such patent will not be issued,  Calypte's royalty obligation shall
terminate in the United States of America on the tenth (10th) anniversary of the
Effective Date.

         4.3. All royalty payments payable under this Agreement shall be paid on
a quarterly  basis,  within  forty-five  (45) days after March 31st,  June 30th,
September 30th and December 31st of each year.

                                       4
<PAGE>

         4.4. All royalty payments paid by Calypte under this Agreement shall be
paid in the lawful currency of the European Union (euros).

         4.5.  Calypte  shall keep,  and shall  require its  Affiliates to keep,
true,  complete  and  accurate  books of  accounts  and  records  together  with
supporting  documentation  for Licensed  Products made,  used or sold under this
Agreement in accordance with generally accepted accounting principles as applied
in the United  States  appropriate  to  determine  the amount of  royalties  due
hereunder and their proper  payment.  Such records and supporting  documentation
shall be open during normal  business hours upon reasonable  advance notice,  at
mutually agreed upon times, for the longer of three (3) years or the time during
which such material  should be held in  accordance  with  applicable  accounting
regulations following the end of the calendar year to which they pertain, to the
inspection of an independent certified public accountant retained by Ani for the
sole  purpose of  verifying  the  accuracy of the royalty  payments  made to Ani
hereunder.  Such certified public  accountant shall be entitled to obtain copies
of any of Calypte's or its Affiliates'  documents  reasonably  necessary for the
verification of the amount of royalties and their proper payment. If in dispute,
such records shall be kept until the dispute is settled.  Inspection shall be at
Ani's  expense,  unless the inspector  concludes that the amount payable that is
stated in a report is  understated by two percent (2%) or more or royalties were
not paid when due, in which case  Calypte  shall in addition to any other remedy
that may be available to Ani at law or in equity, pay Ani's reasonable  expenses
incurred in connection with the inspection shall be paid by Calypte. The Parties
agree that any certified public accountant  inspecting  Calypte's books pursuant
to this  Section  4.3 shall  not  disclose  to Ani any  information  other  than
information  relating to the  accuracy of reports and payments  made  hereunder.
Such accountant  shall be required to execute an agreement with Calypte agreeing
to the  confidentiality  provisions  set forth in this Section 4.3.  Information
disclosed  to  Ani  as a  result  of an  inspection  shall  be  subject  to  the
confidentiality provisions set forth in Section 8.

         4.6. In the event Calypte fails to pay the royalties  described in this
Section 4 and  Exhibit B on or before the last day of the time  period set forth
in Section 4.2,  such  royalties  shall bear  interest  from and after such date
until paid at a per annum rate equal to the US prime  lending  rate (Prime Rate)
plus three (3) percent as quoted in The Wall Street  Journal for the thirty (30)
day period ending on the payment due date.  Each such royalty  payment when made
shall be  accompanied  by all  accrued  and unpaid  interest.  Ani shall also be
entitled to compensation for its reasonable collection costs.

         4.7. Calypte shall,  within forty-five (45) days after March 31st, June
30th,  September 30th and December 3lst of each year of this Agreement,  deliver
to Ani a true and accurate written  accounting  royalty report for each calendar
quarter.  Each such report shall set forth per Licensed Products per Analyte per
each country in which the Licensed  Products have been sold:  (i) the Net Sales;
(ii) all  deductions  from Net Sales made by Calypte  pursuant to Section  1.10;
(iii) the  royalties  payable  by  Calypte to Ani  pursuant  to Section  4.1 and
Exhibit B; and,  (iv) the product  description/name  per catalog  code.  Calypte
shall  cooperate  fully  with any  request by an  authority  or court to deliver
information about the buyers of Licensed Products  distributed by Calypte or its
Affiliates.

                                       5
<PAGE>

         4.8. Each royalty  report shall be made and sent by the due date to the
following addressees or any other address that Ani may provide in writing:

                           Ani Biotech Oy
                           Museokatu 13 B
                           00100 Helsinki Finland
                           Attn:  Dr. Aimo Niskanen, CEO
                           Telephone:  +358-20-1557515
                           Facsimile:  +358-20-1557517
                           Email:  aimo.niskanen@anibiotech.fi

5. Purchase of Manufacturing Equipment.

         5.1. Calypte shall purchase  Manufacturing  Equipment  according to the
following price schedule:

                                         Quantity               Purchase Price
LP-03A Line Printing Machine
                                             1                    54,800 euro
AM-03A Assembling Machine - Short
Slides                                       1                    76,600 euro
CA-03A Conjugate Application Machine         1                    24,320 euro
ABM-03A Automatic Bottling Machine           1                    51,120 euro
Sample Applicator Device Assembly
Machine                                      1                    26,000 euro
                                                                  -----------
                                      Total Purchase Price:      232,840 euro

         5.2.  The  purchase  price  for  Manufacturing  Equipment  set forth in
Section 5.1 shall include:  (i) installation at a Calypte  designated  facility;
(ii) a one (1) year  factory  warranty  for parts and  labor;  (iii)  reasonable
training of Calypte  personnel in the use and  maintenance of the said equipment
at the  facilities  of Ani in Finland on a time as mutually  agreed  between the
parties; and, (iv) a reasonable supply of spare parts as mutually agreed between
the parties.

         5.3.  Calypte  shall make  payment for the  purchase  of  Manufacturing
Equipment set forth in Section 5.1 according to the following schedule:

                  5.3.1.  Seventy-seven  thousand  six  hundred  thirteen  Euros
(77,613 euro) payable in cash or in shares of Calypte common stock,  pursuant to
Section 7.1.2 and Section  7.1.2.1,  upon the Effective Date, or within five (5)
business days after the effectiveness of the Registration Statement set forth in
Section 7.1.1;

                  5.3.2.  Seventy-seven  thousand  six  hundred  thirteen  Euros
(77,613 euro) due upon inspection and acceptance of  Manufacturing  Equipment at
Ani's facility prior to shipment to Calypte, and payable in shares of registered
Calypte  common  stock,  or cash, or a combination  thereof,  at Calypte's  sole
discretion; and,

                                       6
<PAGE>

                  5.3.3.  Seventy-seven  thousand  six  hundred  fourteen  Euros
(77,614 euro) due upon inspection,  acceptance and installation of Manufacturing
Equipment at Calypte's designated facility,  and payable in shares of registered
Calypte  common  stock,  or cash, or a combination  thereof,  at Calypte's  sole
discretion.

         5.4.  In  the  event  Ani  shall  make  improvements  to  Manufacturing
Equipment, Ani shall make available to Calypte all such improvements at mutually
agreed terms.

         5.5. Ani shall provide  Calypte at no additional  cost all existing and
any updated engineering  drawings,  diagrams,  schematics and blueprints for all
molds used to manufacture all plastic sample  applicator  device parts and rapid
test device parts assembled by Manufacturing  Equipment to be used solely within
the limits of the license  granted in Section 2. Ani shall  remain the owner of,
and shall retain all rights in and to, all such technical documentation.

         5.6.  Calypte  shall have the option to  purchase  all  plastic  sample
applicator  component  device  parts  and  rapid  test  device  component  parts
assembled by Manufacturing Equipment directly from Ani at a price to be mutually
agreed  between the parties.  In no case shall the price paid by Calypte  exceed
one  hundred  twenty  percent  (120%) of the  price Ani pays for said  component
parts. In the event, Ani's purchase price for said component parts decreases due
to the increased unit volume resulting from Calypte's purchase of said component
parts,  Calypte  shall be granted the same discount from the supplier as Ani for
the purchase of said component.

         5.7.  Ani  shall  provide  Calypte  with  a  fully  annotated  detailed
Bill-of-Materials (BOM) for all parts assembled by Manufacturing Equipment to be
used  solely for the purpose of repair of and  acquiring  of spare parts for the
Manufacturing  Equipment.   Such  BOM  shall  include  the  units  required  per
sub-assembly,  a listing of all vendors for component parts,  sub-assemblies and
final assemblies,  and any other information necessary to identify the requisite
parts needed for each sub-assembly and final assembly.

         5.8. Both parties shall conduct quality  control and assurance  testing
on Manufacturing Equipment prior to shipment to Calypte in order to confirm that
Manufacturing   Equipment   functions   in   accordance   with   the   technical
specifications  set forth in Exhibit A or documentation  delivered together with
Manufacturing Equipment.

         5.9. Ani shall  package and ship  Manufacturing  Equipment to Calypte's
designated  facility.  Manufacturing  Equipment  shall be properly  packaged and
labeled in accordance with industry standards and customs at Ani's expense.  All
such shipments shall be FOB Helsinki, Finland.

         5.10.   Manufacturing   Equipment  received  by  Calypte  at  Calypte's
designated facility shall be subject to quality control testing by Calypte; such
quality control procedures used by Calypte to test Manufacturing Equipment shall
be the same quality  control  testing  procedures  used by Ani, and agreed to by
Calypte, to test Manufacturing Equipment prior to shipment from Finland.

                                       7
<PAGE>

         5.11. In the event there is a defect or non-conformity in Manufacturing
Equipment upon receipt by Calypte at Calypte's  designated  facility,  Ani shall
promptly correct or repair such defect or non-conformity at Calypte's designated
facility, or in the event Ani is unable to promptly effect said repair,  Calypte
shall have the right to return any such defective Manufacturing Equipment to Ani
for replacement.  The shipping cost for returning any defective  equipment shall
be at Ani's sole expense.

         5.12. Any remarks or  reclamations  regarding  Manufacturing  Equipment
shall be made within two (2) weeks from the date of completion  of  installation
by Ani at Calypte's designated facility. Should Ani not receive any such notices
or remarks from Calypte stating  non-compliance  of such equipment by the end of
the two (2) week period following completion of its installation,  Calypte shall
be deemed to have  approved and accepted the delivery and  installation  of such
equipment.

6. Technology Transfer.

         6.1. Ani and Calypte shall work together to reformat  Calypte's current
HIV  dipstick  rapid  test  device and assay to  perform  as  Licensed  Products
(hereinafter  known as the "Project").  Prior to commencing work on the Project,
Ani and Calypte shall prepare a mutually agreed upon research plan  (hereinafter
known as the "Scope of Work") to define  specifications,  milestones  and goals.
The results of the Project shall be the sole and exclusive property of Calypte.

         6.2.  Ani and  Calypte  shall each be  responsible  for their own costs
during the Project and the transfer of Licensed  Technology from Ani to Calypte.
Calypte may,  under  mutually  agreed terms,  hire Ani to consult on the further
development of Licensed  Products in preparation  for the  commencement of human
clinical trials.

         6.3. Each party shall  designate a Project  Director to represent their
interests  and serve as a central  point of contact  during the  Project and the
transfer of Licensed Technology from Ani to Calypte.

         6.4. As part of the Project,  Ani shall  permit a reasonable  number of
technical personnel designated by Calypte to study the design and manufacture of
products  resulting  from the Project at Ani's place of business.  Calypte shall
advise Ani, in advance,  the names,  qualifications and probable lengths of stay
of  Calypte's  designated  personnel  desiring  to visit  Ani.  Ani  shall  make
available  qualified  personnel  for  consultation  with,  and  training of such
Calypte's  personnel.  The cost for  transportation,  meals,  lodging  and other
expenses  of  Calypte's  personnel  dispatched  for  training  shall be borne by
Calypte.  Such  Calypte's  personnel  shall  fully  comply  with Ani's  security
regulations and personnel rules.

         6.5. As part of the Project, Ani shall transfer to Calypte all know-how
necessary  to  allow  Calypte  to  develop  and  manufacture  Licensed  Products
including  but not limited to all  specifications  for reagents  and  materials,
formula,  manufacturing,  analytical and testing procedures, release, packaging,
and other processes  contained in any document  related to Licensed  Technology,
Licensed Products and the Project including all master formulas and process flow
diagrams.

                                       8
<PAGE>

         6.6. The transfer of Licensed  Technology  from Ani to Calypte shall be
accomplished  in three  (3)  phases,  and  Licensed  Technology  shall be deemed
transferred upon the successful completion of Phase 3 as set forth below:

                  6.6.1.   Phase  1:  Ani  and  Calypte   shall   demonstrate  a
laboratory-scale prototype of an HIV-1/2 rapid test based on Licensed Technology
meeting the specifications set forth in the Scope of Work.

                  6.6.2.  Phase 2: Ani and Calypte shall  demonstrate,  at Ani's
facility,  the successful  pilot-scale  manufacturing  of the HIV-1/2 rapid test
developed  in Section  6.6.1  using the  Manufacturing  Equipment  purchased  by
Calypte.

                  6.6.3.  Phase  3:  Ani  and  Calypte  shall  demonstrate,   at
Calypte's  facility,  the successful  pilot-scale  manufacturing  of the HIV-1/2
rapid  test  developed  in  Section  6.6.2  using  the  Manufacturing  Equipment
purchased by Calypte.

7. Payments.

         7.1. Common Stock Payments.

                  7.1.1.  Within  thirty  (30)  days  from the  Effective  Date,
Calypte shall file a Registration  Statement  with the United States  Securities
and Exchange Commission (SEC) in accordance with the provisions contained in the
Securities  Act of 1933,  as  amended,  for all shares of Calypte  common  stock
payable to Ani hereunder.

                  7.1.2.  The pricing of the shares of Calypte common stock used
for payment of the 300,000 euro  License Fee set forth in Section  3.1.1 and the
77,613  euro  payment for  Manufacturing  Equipment  set forth in Section  5.3.1
(hereinafter  the  "Pricing")  shall  be at  Ani's  option,  either:  (i) on the
Effective Date, or (ii) on the date of the filing of the Registration  Statement
set forth in Section 7.1.1, provided however, the Pricing is equal to or greater
than the Threshold Price.

                  7.1.2.1.  In the event the Pricing is less than the  Threshold
Price,  Calypte  shall (i) make payment in cash for the 300,000 euro License Fee
set forth in  Section  3.1.1  and the  77,613  euro  payment  for  Manufacturing
Equipment  set  forth in  Section  5.3.1,  or (ii) Ani may  elect to  accept  an
equivalent number of shares of Calypte common stock priced at $0.40 per share as
payment for the  300,000  euro  License  Fee set forth in Section  3.1.1 and the
77,613 euro payment for Manufacturing Equipment set forth in Section 5.3.1.

                  7.1.3. All Calypte common stock  transferred to Ani as payment
for any portion of the 700,000 euro License Fee set forth in Section 3.1.2,  and
as payment for any portion of the 155,227 euro Manufacturing Equipment set forth
in Sections  5.3.2 and 5.3.3,  shall be  registered  with the SEC at the time of
said transfer.

                                       9
<PAGE>

                  7.1.4.  Calypte  shall  comply  with Best  Price and  Currency
Exchange Rate provisions as defined  elsewhere in this Agreement when making all
payments for License Fee, Royalty, and Manufacturing Equipment.

                  7.1.5.  All payments  made by Calypte in the form of shares of
Calypte common stock shall be deposited in Ani's brokerage account at:

                           Joseph Stevens & Company, Inc.
                           59 Maiden Lane
                           New York, NY 10038
                           Account Number:  7U5961641
                           Attn:  Mr. Fabio Migliaccio, Director of Operations
                           Telephone:  (212) 361-3000
                           Facsimile:  (212) 361-3333
                           Email:  fmigliaccio@josephstevens.com

                  7.1.6.  In the event Calypte fails to make the payments in the
form of shares of Calypte common stock or cash pursuant to Section 3 and Section
5, such delayed  payments shall bear interest from and after the due date of the
payment as set forth in the abovementioned  Sections 3 and 5 until paid at a per
annum  rate  equal to the US prime  lending  rate  (Prime  Rate)  plus three (3)
percent as quoted in The Wall  Street  Journal  for the  thirty  (30) day period
ending on the payment due date.  Each such  delayed  payment  when made shall be
accompanied by all accrued and unpaid interest  deposited via bank wire transfer
in Ani's bank account as described in Section 7.2.1.  Ani shall also be entitled
to compensation for its collection costs.

         7.2. Cash Payments.

                  7.2.1.  All payments made by Calypte in the form of cash shall
be made in Euros and be electronically deposited via bank wire transfer in Ani's
bank account at:

                           Nordea Bank Oy
                           Helsingin Yrityspankki
                           Korkeavuorenkatu 45, 00020 NORDEA
                           FINLAND
                           Account Number:  20011-800382023
                           Swift:  NDEAFIHH
                           IBAN:  FI9120011800382023
                           Telephone:  +358-9-16541801

         7.3. In the event that any taxes,  withholding or otherwise, are levied
by any government  taxing authority in connection with accrual or payment of any
royalties  payable to Ani under this Agreement,  Calypte shall have the right to
pay such taxes to the local tax  authorities on behalf of Ani and the payment to
Ani of the net amount due,  after  reduction by the amount of such taxes,  shall
fully satisfy Calypte's royalty obligations under this Agreement,  provided that
appropriate documentation of such tax payment, including evidence of payment and
receipt or any other appropriate documentation, is provided to Ani.

                                       10
<PAGE>

8. Confidentiality.

         8.1. Each party shall protect all Confidential Information of the other
party  with  the  same  degree  of care as it uses to  avoid  unauthorized  use,
disclosure,  publication or dissemination of its own confidential information of
a similar nature, but in no event less than a reasonable degree of care.

         8.2. Except as provided in this Agreement,  neither party shall use for
its own  benefit  or the  benefit  of any Third  Party,  or  disclose,  publish,
release,   transfer  or  otherwise  make  available  to  any  Third  Party,  any
Confidential  Information  of the other party  without the other  party's  prior
written  consent.  Each of  Calypte  and Ani,  however,  shall be  permitted  to
disclose Confidential Information of the other to contractors and Third Parties,
and its employees,  Affiliates,  accountants,  attorneys and other agents to the
extent such disclosure is reasonably necessary for the performance of its duties
and obligations  hereunder or, with respect to Calypte, its use and enjoyment of
the  Licensed  Technology  and  Improvements.  Each of Calypte  and Ani shall be
responsible  for any  violation  of the  confidentiality  obligations  set forth
herein by any of the foregoing.

         8.3.  The  obligations  in  this  Section  8  shall  not  restrict  any
disclosure of  Confidential  Information  received by one party (the  "Receiving
Party") from the other party (the "Disclosing  Party") where the Receiving Party
can  demonstrate  that:  (a) such  Confidential  Information  was  independently
developed by the Receiving Party prior to its receipt thereof without  violating
its obligations  hereunder or any of the Disclosing Party's  proprietary rights;
(b) such  Confidential  Information  is or becomes  publicly  known  (other than
through  the  unauthorized   disclosure  by  the  Receiving  Party);   (c)  such
Confidential  Information  was already known to the Receiving Party prior to its
receipt thereof without any obligation of confidentiality; (d) such Confidential
Information  is received by the  Receiving  Party from a Third Party without any
obligation of  confidentiality;  or (e) the Receiving Party is required to do so
pursuant to any applicable  law (provide that the Receiving  Party shall provide
reasonable prior written notice to the Disclosing Party of such disclosure).

         8.4. In addition to the foregoing,  nothing contained in this Agreement
shall   supercede   the   confidentiality   requirements   set   forth   in  the
Confidentiality  Agreement signed by the parties dated February 2, 2004, and its
Amendment  signed by the parties on February 29, 2004 shall remain in full force
and effect.

9. Joint Investigation and Freedom to Operate Opinion.

         9.1. The parties deemed that,  prior entering into this  Agreement,  it
was in their  mutual best  interests to ensure that  Calypte's  sale of Licensed
Products did not infringe intellectual property rights of Third Parties.

         9.2.  Prior to entering  into this  Agreement,  the parties  obtained a
Freedom to Operate  Opinion from competent  patent counsel  concerning  Licensed
Technology.  The parties have agreed to share equally the cost of obtaining said
Freedom to Operate Opinion.

                                       11
<PAGE>

10. Term and Termination.

         10.1. This Agreement,  unless earlier terminated in accordance with the
terms set forth herein,  shall continue until the expiration of all Valid Patent
Claims. In the event no patents covering Licensed Technology issue in the United
States of America  within ten (10) years of the Effective  Date,  this Agreement
shall terminate with respect to the United States of America but shall remain in
force and effect outside of the United States of America until expiration of all
Valid Patent Claims.

         10.2. This Agreement may be terminated by Calypte at any time by giving
written notice to Ani. The  termination  shall be effective six (6) months after
the date of notice.  If the Agreement is  terminated  by Calypte,  Calypte shall
cease  manufacturing  and selling Licensed  Products within six (6) months after
the date of said notice.

         10.3.  This  Agreement may be  terminated by Ani if Calypte  materially
breaches this  Agreement  and Calypte has not cured such material  breach within
ninety (90) days after  receipt of written  notice to Calypte by Ani  specifying
the nature of such alleged material breach. Failure of Calypte to pay any amount
specified under this Agreement  within thirty (30) days after the due date shall
be deemed a material breach,  which shall entitle Ani to terminate the Agreement
with immediate effect with a written notice to Calypte.

         10.4.  This  Agreement  shall  terminate  upon (i) an  adjudication  of
Calypte as bankrupt or  insolvent,  or admission in writing of its  inability to
pay its  obligations  as they mature;  (ii) an assignment  of this  Agreement by
either Party for the benefit of creditors;  (iii) the appointment of, or Calypte
applying for or consenting to the appointment of, a receiver, trustee or similar
officer for a substantial  part of its property;  (iv) the institution of or any
act of Calypte instituting any bankruptcy,  insolvency  arrangement,  or similar
proceeding;  or (v) the  issuance  or levy of any  judgment,  writ,  warrant  of
attachment or execution or similar  process  against a  substantial  part of the
property of Calypte.  Calypte may apply for  reinstatement  of this Agreement if
either of conditions (iii) or (v) is removed within ninety (90) days.

         10.5. Section 8  (Confidentiality),  Section 10 (Term and Termination),
Section 11 (Dispute  Resolution),  Section 12  (Representations,  Warranties and
Limitation  of  Liability),  and Section 13 (General  Provisions)  shall survive
termination of this Agreement.

11. Dispute Resolution.

         11.1.  Any dispute,  controversy  or claim  arising from or relating to
this  Agreement,  or the breach,  termination  or  invalidity  thereof,  will be
settled by  arbitration  in Hamburg,  Germany,  in accordance  with the Rules of
Arbitration  of the  International  Chamber of Commerce  (the "Rules") by one or
more  arbitrators  appointed  in  accordance  with the  Rules.  The award of the
arbitration  will be final and binding upon the parties without appeal or review
except as permitted by German law.

                                       12
<PAGE>

12. Representations, Warranties and Limitation on Liability.

         12.1. Calypte represents and warrants:  (a) It is a corporation validly
existing and in good standing  under the laws of the State of Delaware;  (b) The
execution,  delivery and  authority to execute and deliver this  Agreement  have
been duly authorized by all necessary  corporate  action on the part of Calypte;
(c) It has the  corporate  power and  authority  to  execute  and  deliver  this
Agreement  and to perform its  obligations  under this  Agreement;  and, (d) All
shares of Calypte  common  stock have been duly  authorized  and upon  issuance,
pursuant to the terms hereof and for the consideration herein set forth, will be
validly issued, fully paid and nonassessable.

         12.2.  Ani  represents  and warrants:  (a) It is a corporation  validly
existing and in good standing under the laws of the country of Finland;  (b) The
execution,  delivery and  authority to execute and deliver this  Agreement  have
been duly authorized by all necessary  corporate  action on the part of Ani; (c)
It has the corporate  power and authority to execute and deliver this  Agreement
and to perform its obligations  under this  Agreement;  (d) Other than the grant
set forth herein, Ani has not encumbered,  restricted,  transferred or otherwise
burdened the Licensed Technology or Manufacturing Equipment; (e) It is not aware
of  any  claim  of  infringement  by any  other  party  in  and to the  Licensed
Technology;  (f)  Manufacturing  Equipment shall be merchantable and fit for the
particular purpose it is being sold for hereunder;  and, (g) Except as expressly
set forth  herein,  Ani hereby  disclaims  and negates  any and all  warranties,
whether  express  or  implied,  with  respect  to the  Licensed  Technology  and
Improvement, or any rights hereunder transferred,  including but not limited to,
any IMPLIED  WARRANTY OF  MERCHANTABILITY,  NON-INFRINGEMENT  OR FITNESS FOR ANY
PARTICULAR PURPOSE.  Without limiting the generality of the foregoing, Ani makes
no representations or warranties as to the patentability,  noninfringement,  use
or other application of the Licensed Technology or any Improvement, or as to the
likelihood of the success of any research,  development,  testing,  marketing or
other utilization of the Licensed Technology or any Improvement.

         12.3. Under no circumstances  shall either party be liable to the other
party for any consequential,  incidental, special, indirect or exemplary damages
arising out of or related to this Agreement,  whether in contract,  tort, strict
liability or any other legal theory,  including without limitation,  damages for
loss of profits,  business interruption,  or for any claim or demand against one
party by any other party, or other pecuniary loss.

13. General Provisions.

         13.1.  Neither this  Agreement nor any rights or obligations of a Party
under this  Agreement  may be assigned in whole or in part by such Party without
the prior written consent of the other Party,  except that each Party may assign
this Agreement to an Affiliate or in connection with any merger, reorganization,
or consolidation  with or into another Entity, or any sale or transfer of any of
its assets or  business  to a Third  Party,  provided  however,  the Third Party
agrees in  writing  to assume  the  assigning  Party's  obligations  under  this
Agreement. Any attempted assignment in violation hereof will be void.

                                       13
<PAGE>

         13.2.  This  Agreement  will  bind  and  inure  to the  benefit  of the
respective successors and permitted assigns of the parties.

         13.3. This Agreement shall be construed and enforced in accordance with
the laws of the country of Germany without giving effect to its conflicts of law
principles.

         13.4. If any provision of this  Agreement is  unenforceable  or invalid
under  any  applicable  law or is so held by  applicable  court  decision,  such
unenforceability  or invalidity will not render this Agreement  unenforceable or
invalid as a whole and such  provisions will be changed and interpreted so as to
best accomplish the objectives of such unenforceable or invalid provision within
the limits of applicable law or applicable court decisions.

         13.5.  The failure of either party to require  performance by the other
party of any  provision  of this  Agreement  will not  affect  the full right to
require such performance at any time  thereafter;  not will the waiver by either
party of a breach of any  provision  of this  Agreement be taken or held to be a
waiver of the provision itself.

         13.6.  Ani and Calypte  shall consult with each other and shall conduct
themselves  in a  manner  consistent  with  all  current  regulatory  guidelines
governing  the  manufacture  and  sale of human  in  vitro  clinical  diagnostic
products.  The  parties  shall use  commercially  reasonable  efforts to provide
requisite  facilities,  staff and supplies necessary to fulfill their respective
obligations  as set forth in this  Agreement.  Each party  agrees to execute and
deliver  any  and  all  documents,  and to  perform  such  other  acts as may be
reasonably  necessary or expedient to carry out and make  effective the purposes
and transactions contemplated by this Agreement.

         13.7.  Information  developed  and  produced  during  the course of the
parties  fulfilling  their  obligations  as set  forth in the  Agreement  may be
translated  into  regulatory  agency  filings and  manufacturing,  packaging and
quality control procedures by the parties which will be reviewed and approved by
both parties. All such information,  documentation and regulatory agency filings
shall be the sole property of Calypte.  Calypte shall be solely  responsible for
complying with  requirements for testing,  filings,  marketing,  advertising and
other  compliance  with  applicable  laws for Licensed  Products sold by Calypte
within the Territory.

         13.8.  Neither  party shall be  responsible  for any defaults or delays
that are due to causes  beyond  the  party's  control,  including,  but  without
limitation,  acts of God or public  enemy,  acts of a  government  or  terrorist
group, or total or partial product recall (actual or threatened), fire, flood or
other natural disasters, embargoes, accidents, explosions, strike or other labor
disturbances  (regardless  of the  reasonableness  of  the  demands  of  labor),
shortages  of fuel,  power or raw  materials,  inability  to obtain or delays of
transportation  facilities,  incidents  of war,  or  other  events  causing  the
inability of the party, acting in good faith with due diligence,  to perform its
obligations or otherwise refrain from committing a breach.

                                       14
<PAGE>

         13.9.  Neither  party  shall  issue  or cause to be  issued  any  press
release,  public  announcement or disclosure of any kind or nature whatsoever or
otherwise  disclose the  existence  of an  agreement  between the parties or the
transactions  contemplated  hereby  except as is  required by law, or SEC public
disclosure  reporting  requirements,  or to the extent that both parties jointly
agree to such press release, public announcement or disclosure in advance and in
writing.

         13.10.  Nothing in this  Agreement  will be  construed  as creating any
agency,  partnership,  or other form of joint  enterprise  between the  parties.
Neither party will have the authority to act or create any binding obligation on
behalf of the other party and neither  party will  represent  to any third party
that it has the  authority to act or create any binding  obligation on behalf of
the other party.

         13.11. This Agreement may be executed in two or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

         13.12. This Agreement,  together with the Exhibits hereto,  constitutes
the entire  agreement  between the Parties as to the subject matter hereof,  and
supercedes   all   prior   negotiations,    representations,    agreements   and
understandings  whether  oral or written  regarding  such subject  matter.  This
Agreement  may be modified or amended only by a writing  executed by  authorized
representatives of both of the parties.

         13.13. All notices, consents, waivers and other communications intended
to have legal effect under this Agreement must be in writing,  must be delivered
to the  other  party  at the  address  set  forth  below by  personal  delivery,
certified mail,  postage pre-paid,  or an internationally  recognized  overnight
courier, and will be effective upon receipt (or when delivery is refused).  Each
party may change its address for receipt of notices by giving  notice of the new
address to the other party pursuant to this Section:

                           If to Ani:

                                      Ani Biotech OY
                                      Museokatu 13 B
                                      00100 Helsinki Finland
                                      Attn:  Dr. Aimo Niskanen, CEO
                                      Telephone:  +358-20-1557515
                                      Facsimile:  +358-20-1557517
                                      Email:  aimo.niskanen@anibiotech.fi

                           If to Calypte:

                                      Calypte Biomedical Corporation
                                      5000 Hopyard Road, Suite 480
                                      Pleasanton, CA 94588 USA
                                      Attn:  Mr. Richard Brounstein, EVP & CFO
                                      Telephone:  (925) 730-7207
                                      Facsimile:  (925) 730-0146
                                      Email:  rbrounstein@calypte.com

                                       15
<PAGE>

                                 SIGNATURE PAGE

       IN WITNESS  WHEREOF,  Ani and Calypte have executed this  Agreement as of
the date first shown above.

FOR ANI BIOTECH OY:                FOR CALYPTE BIOMEDICAL:

/s/ Aimo Niskanen                  /s/ J. Richard George
-----------------------------      -------------------------------
DR. AIMO NISKANEN                  DR. RICHARD GEORGE

President & CEO                    President & CEO
-----------------------------      -------------------------------
TITLE                              TITLE

                                       16
<PAGE>

                                    EXHIBIT A

                             MANUFACTURING EQUIPMENT

                                       17
<PAGE>

AUTOMATIC BOTTLING MACHINE                                            [LOGO]
2004-08-11                                                            ANIBiotech
Page 1 of 2
--------------------------------------------------------------------------------

AUTOMATIC BOTTLING MACHINE
ABM-03A

Introduction:

o     Automatic feeding System for small vials and caps (Vial, Sarstedt 72.694,
      2ml)
o     Automatic feeding for liquid (Dispensette, Bottle-Top Dispenser)
o     Adjustable speed of machine (100 - 1600 bottles / hour)

                                [PHOTO OMITTED]

================================================================================

TECHNICAL INFORMATION

================================================================================

================================================================================

AUTOMATIC BOTTLING MACHINE                    ABM-03A

================================================================================

Power                                         220 - 230 V,50 Hz
--------------------------------------------------------------------------------
Body                                          Aluminium/steel
--------------------------------------------------------------------------------
Compressed Air Equipment                      Need for air about 60 l/min
--------------------------------------------------------------------------------
Vibration Vat for Vial                        0 550 mm, 519 W
--------------------------------------------------------------------------------
Vibration Vat for Cap                         0 250 mm, 240 W
--------------------------------------------------------------------------------
Speed Control                                 100-1600 bottles/h (adjustable)
--------------------------------------------------------------------------------
Emergency Stop                                Safety Switch
--------------------------------------------------------------------------------
Bottle-Top Dispenser                          Dispensette
--------------------------------------------------------------------------------
Vials and caps                                Sarstedt no 72.694, 2 ml
--------------------------------------------------------------------------------
Length                                        1000 mm
--------------------------------------------------------------------------------
Width                                         900 mm
--------------------------------------------------------------------------------
Height                                        1250 mm
--------------------------------------------------------------------------------
Weight                                        120 kg
--------------------------------------------------------------------------------

                                       18
<PAGE>

ASSEMBLING MACHINE                                                    [LOGO]
2004-08-11                                                            ANIBiotech
Page 1 of 2
--------------------------------------------------------------------------------

ASSEMBLING MACHINE - SHORT SLIDES
AM-03A

Introduction:

o     One cassette type per machine
o     Small need for space
o     Single operator
o     Automatic cutting and feeding system of laminated strip
o     Assembles the cutted strip, pill and cover
o     Pick and push mechanism
o     Manual feeding of bottom and cover cassettes into feeding belts
o     Adjustable speed up to 1800 cassettes/hour

                                [PHOTO OMITTED]

================================================================================

TECHNICAL INFORMATION

================================================================================

--------------------------------------------------------------------------------
Body                                          Industrial table, 1500 x 750 mm,
                                              plastic/steel
--------------------------------------------------------------------------------
Power                                         230 V, 50 Hz
--------------------------------------------------------------------------------
Compressed Air Remove Button                  Safety Switch
--------------------------------------------------------------------------------
Cutting Width                                 Depends of cassette type (X)
                                              (5mm)
--------------------------------------------------------------------------------
Backing Plastic                               Depends of cassette type (X)
                                              (71mm)
--------------------------------------------------------------------------------
Speed Control                                 1800 pc/h (adjustable)
--------------------------------------------------------------------------------
Emergency Stop                                Safety Switch
--------------------------------------------------------------------------------
Feeding System for Cassettes                  2x18 W
--------------------------------------------------------------------------------
Cutting Blade                                 Thickness 0.25mm
--------------------------------------------------------------------------------
Compressed Air Equipment                      Need for air about 120 l/min
--------------------------------------------------------------------------------
Length                                        1500 mm
--------------------------------------------------------------------------------
Width                                         1100 mm
--------------------------------------------------------------------------------
Height                                        1120 mm
--------------------------------------------------------------------------------
Weight                                        149 kg
--------------------------------------------------------------------------------
Vibration Vat for Pills (Drying Pill)         Option
--------------------------------------------------------------------------------
Drying Pill                                   Option
--------------------------------------------------------------------------------

(X)   The cassette type must be agreed with Ani Biotech before the manufacturing
      of the assembling machine can be started

                                       19
<PAGE>

CONJUGATE APPLICATION                                                 [LOGO]
2004-08-11                                                            ANIBiotech
Page 1 of 2
--------------------------------------------------------------------------------

CONJUGATE APPLICATION
CA-03A

Conjugate Application for cold and latex conjugation

Introduction:

o     New model - improved version
o     Reel-To-Reel system
o     Dispensing the reagents with peristaltic pump (Watson Marlow 323 S)
o     Holder of feeding nozzle
o     Drying oven with heater
o     Collection reel in the end of the process
o     Digital Speed control (3-5) meters / minute)
o     Machine will be assembled on a table - need for space is small

                                [PHOTO OMITTED]

================================================================================

TECHNICAL INFORMATION

================================================================================

--------------------------------------------------------------------------------
CONJUGATE APPLICATION                         CA-03A
--------------------------------------------------------------------------------
Power                                         230 V, 50 Hz
--------------------------------------------------------------------------------
Body                                          Aluminium
--------------------------------------------------------------------------------
Input and collection reel                     0 360/240/60 mm
--------------------------------------------------------------------------------
Supporting Input and Collect Reel             Aluminium/Steel
--------------------------------------------------------------------------------
Speed Control                                 3-5 meter/min
--------------------------------------------------------------------------------
Protective Plates                             Plastic/aluminium
--------------------------------------------------------------------------------
Dry Air Fans                                  2 x 1400 W
--------------------------------------------------------------------------------
Blocking                                      Peristaltic Pump, Watson Marlow
                                              323 S
--------------------------------------------------------------------------------
Length                                        3400 mm
--------------------------------------------------------------------------------
Width                                         800 mm
--------------------------------------------------------------------------------
Height                                        780 mm (+ table height 700-900 mm)
--------------------------------------------------------------------------------
Weight                                        100 kg
--------------------------------------------------------------------------------
Motor                                         250 W
--------------------------------------------------------------------------------
Tube for peristaltic pump                     Watson Marlow - 0 0.79 mm
--------------------------------------------------------------------------------

                                       20
<PAGE>

LINE PRINTING MACHINE                                                 [LOGO]
2004-08-11                                                            ANIBiotech
Page 1 of 3
--------------------------------------------------------------------------------

LINE PRINTING MACHINE FOR NITROCELLULOSE
LP-03A

Reel-To-Reel Line Printing System

Introduction:

o     The  system  includes  the  place  for  dispensing  the  reagents  with  a
      possibility to control the lines easily by visually
o     Dispensing System (Offered separately)
o     Lightning table for controlling the lines visually
o     Drying Unit for drying the reagents lines
o     Blocking Unit to block the nitrocellulose (Peristaltic Pump, Watson Marlow
      323)
o     Drying Unit after blocking
o     Collecting Reel System

                                [PHOTO OMITTED]

                                       21
<PAGE>

LINE PRINTING MACHINE                                                 [LOGO]
2004-08-11                                                            ANIBiotech
Page 2 of 3
--------------------------------------------------------------------------------

================================================================================

TECHNICAL INFORMATION

================================================================================

--------------------------------------------------------------------------------
REAGENS UNIT
--------------------------------------------------------------------------------
Power                                         230 V, 50 Hz
--------------------------------------------------------------------------------
Body                                          Indutrial table, 2250 x 750 mm
--------------------------------------------------------------------------------
Input Reel                                    0 500/400/60 mm
--------------------------------------------------------------------------------
Supporting of Reel                            Aluminium/Steel/Plastic
--------------------------------------------------------------------------------
Reagent printing table                        Plastic/Aluminium
--------------------------------------------------------------------------------
Lighting of the Table                         Fluorescence tube, 2 x 40W
--------------------------------------------------------------------------------
Reagent Dispensing Machine                    Imagene Technology / Bio Dot
                                              (Offered separately)
--------------------------------------------------------------------------------
Speed  Control                                1-2 m/min (adjustable)
--------------------------------------------------------------------------------
Dry Air Fan                                   1400 W
--------------------------------------------------------------------------------
Blocking Unit                                 Peristaltic Pump; Watson Marlow
                                              323 S
--------------------------------------------------------------------------------
Nozzles (Blocking)                            0 0.7 mm
--------------------------------------------------------------------------------
Nozzle Tube                                   Sarstedt / Watson Marlow 0 0.79 mm
--------------------------------------------------------------------------------
Length                                        3000 mm
--------------------------------------------------------------------------------
Width                                         750 mm
--------------------------------------------------------------------------------
Height                                        1300 mm(table), 25000mm
                                              (Drying Tower)
--------------------------------------------------------------------------------
Weight                                        150 kg
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
DRYING UNIT
--------------------------------------------------------------------------------
Power                                         230 V, 50 Hz
--------------------------------------------------------------------------------
Body                                          Aluminium
--------------------------------------------------------------------------------
Motor                                         550 W
--------------------------------------------------------------------------------
Reels of Drying Unit                          Steel
--------------------------------------------------------------------------------
Bars of Body                                  Aluminium
--------------------------------------------------------------------------------
Protective Plates                             Acryl (Perspex) / Aluminium
--------------------------------------------------------------------------------
Reel                                          0 500/400/60 mm
--------------------------------------------------------------------------------
Speed Control                                 1-2 m/min (adjustable)
--------------------------------------------------------------------------------
Dry Air Fans                                  2x1400 W
--------------------------------------------------------------------------------
Reflection Plates of Dry Air                  Aluminium
--------------------------------------------------------------------------------
Length                                        2800 mm
--------------------------------------------------------------------------------
Width                                         800 mm
--------------------------------------------------------------------------------
Height                                        1170 mm
--------------------------------------------------------------------------------
Weight                                        130 kg
--------------------------------------------------------------------------------

                                       22
<PAGE>

SAMPLING DEVICE ASSEMBLY MACHINE                                      [LOGO]
2004-08-11                                                            ANIBiotech
Page 1 of 2
--------------------------------------------------------------------------------

SAMPLING DEVICE ASSEMBLY MACHINE
SDA-03A (2.5/4.7mm)

Introduction:

o     Single operator
o     Manual speed control
o     Automatic cutting of the laminated strip
o     Automatic cutting of the sample end
o     Makes two samples stick at once
o     Machine will be assembled on a table

                                [PHOTO OMITTED]
           This is a picture of an R&D machine, not a final version.

================================================================================

TECHNICAL INFORMATION

================================================================================

--------------------------------------------------------------------------------
Body                                          Steel
--------------------------------------------------------------------------------
Power                                         230 V, 50 Hz
--------------------------------------------------------------------------------
Protective Plates                             Plastic
--------------------------------------------------------------------------------
Rolling surfaces                              Rubber
--------------------------------------------------------------------------------
Speed Control                                 Up to 1000 pc/h
--------------------------------------------------------------------------------
Emergency Stop                                Safety Switch
--------------------------------------------------------------------------------
Sample stick                                  0 2.5 mm, length 270 mm
--------------------------------------------------------------------------------
Sample end (ready-made stick)                 0 4.7 mm (length 135 mm)
--------------------------------------------------------------------------------
Lamination width                              51 mm
--------------------------------------------------------------------------------
Cutting lenght                                40 mm (Ready sample end length
                                              20 mm)
--------------------------------------------------------------------------------
Cutting Blade                                 Thickness 0.25mm
--------------------------------------------------------------------------------
Compressed Air Equipment                      Need for air about 6l/min
--------------------------------------------------------------------------------
Length                                        600 mm (feeding pipe)
--------------------------------------------------------------------------------
Width                                         900 mm
--------------------------------------------------------------------------------
Height                                        330 mm
--------------------------------------------------------------------------------
Weight                                        33 kg
--------------------------------------------------------------------------------

                                       23
<PAGE>

                                   EXHIBIT B

                                 ROYALTY RATES

                                       24
<PAGE>

<TABLE>
<CAPTION>
                                                             ROYALTY RATES FOR URINE & ORAL FLUID

                                                                                                            SYPHILIS, GONORRHEA,
                                  HIV TEST                  HEPATITIS TEST              HPV TEST               CHLAMYDIA TEST
                              --------------------      -----------------------   ----------------------    ------------------------
----------------
EXCLUSIVE RIGHTS              Professional     OTC      Professional       OTC    Professional      OTC     Professional      OTC
----------------              ------------     ---      ------------       ---    ------------      ---     ------------      ---
<S>                                <C>        <C>          <C>  <C>        <C>       <C>           <C>          <C>           <C>
REGION I COUNTRIES                                         5.0% (Hep C)
(USA, Canada, EU, Japan)           5.0%       10.0%        3.0% (Hep B)    10.0%     7.0%          10.0%        4.0%          10.0%

REGION II COUNTRIES                                        2.0% (Hep C)
(Rest of World)                    2.0%        3.0%        1.0% (Hep B)     5.0%     5.0%           8.0%        2.0%           8.0%

<CAPTION>
                                                             ROYALTY RATES FOR BLOOD & UROGENITAL SWAB

                                                                                                            SYPHILIS, GONORRHEA,
                                  HIV TEST                 HEPATITIS TEST                 HPV TEST             CHLAMYDIA TEST
                              --------------------      -----------------------   ----------------------    ------------------------

--------------------
NON-EXCLUSIVE RIGHTS          Professional     OTC      Professional       OTC    Professional      OTC     Professional      OTC
--------------------          ------------     ---      ------------       ---    ------------      ---     ------------      ---
<S>                                <C>        <C>          <C>  <C>        <C>       <C>           <C>          <C>           <C>
REGION I COUNTRIES                                         3.0% (Hep C)
(USA, Canada, EU, Japan)           3.0%       10.0%        2.0% (Hep B)    10.0%     4.0%          10.0%        3.0%          10.0%

REGION II COUNTRIES
(Rest of World)                    2.0%        3.0%        1.0%             3.0%     3.0%           8.0%        1.0%           8.0%
</TABLE>

                                       25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}]]